Foundry Partners’s Biogen BIIB Stock Holding History

Foundry Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-64,753	Closed	-$18M	–	314
2023 Q1	$18M	Buy	64,753 +7,511	+13%	+$2.08M	1.13%	22
2022 Q4	$15.9M	Buy	57,242 +15,360	+37%	+$4.34M	0.87%	38
2022 Q3	$11.2M	Buy	+41,882	New	+$8.89M	0.7%	47
2015 Q4	–	Sell	-15,502	Closed	-$4.52M	–	266
2015 Q3	$4.52M	Sell	15,502 -1,360	-8%	-$449K	0.4%	84
2015 Q2	$6.81M	Buy	16,862 +5,728	+51%	+$2.3M	0.55%	66
2015 Q1	$4.7M	Buy	+11,134	New	+$4.39M	0.39%	95
2014 Q4	–	Sell	-20,277	Closed	-$6.71M	–	248
2014 Q3	$6.71M	Sell	20,277 -15,290	-43%	-$5.04M	0.62%	67
2014 Q2	$11.2M	Buy	35,567 +6,707	+23%	+$2.02M	1.04%	19
2014 Q1	$8.83M	Buy	28,860 +8,345	+41%	+$2.65M	0.83%	36
2013 Q4	$5.74M	Buy	+20,515	New	+$5.31M	0.52%	79

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Foundry Partners's BIIB Position: Q2 2023 in Review

Foundry Partners sold out of Biogen (BIIB) in Q2 2023, closing a stake of 64,753 shares — an estimated $18M sold.

Foundry Partners first reported a position in BIIB in Q4 2013 and held it in 10 quarters. The position peaked at $18M in Q1 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

Foundry Partners reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
Foundry Partners sold 64,753 Biogen shares in Q2 2023, an estimated $18M.
Foundry Partners first reported a position in Biogen in Q4 2013 and held it in 10 quarters.
Foundry Partners's Biogen position peaked at $18M in Q1 2023.
1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Foundry Partners's 13F filing for Q2 2023, filed 12 Jul 2023.